GLOBOCAN estimates for 2024 list 15.62 million new cancer cases in India, led by breast, oral cavity, lung, colorectal and cervical cancers. Cancer awareness campaigns rightly and strongly stress on early detection and that is why a simple blood test for cancer, one that could catch the disease early, draws so much interest. The reality is less tidy. For most cancers no such test exists and the few that do come with limits worth knowing before a result is read.
This write-up explains the main types of cancer blood tests, what each one is used for, which cancers the common tumour markers point to and where they can mislead. It covers the five markers that Unipath Specialty Laboratory runs (CA-125, CA 19-9, PSA, AFP and CEA) and places blood testing beside cancer screening tests, cancer risk factors and cancer early warning signs.
What a Blood Test for Cancer Can and Cannot Do
Unfortunately, most blood testing in cancer care happens after the diagnosis is made. Doctors use the results to judge how far the disease has spread, estimate its likely course, choose treatment and check if that treatment is working. Once treatment ends, the same markers help in monitoring the disease that remains or comes back. In people with cancer symptoms or a higher inherited risk, a few tests play a limited part in screening.
The limits matter as much as the uses.
- A raised result cannot diagnose cancer on its own. A biopsy, examined by a pathologist, is usually needed to confirm it.
- Non-cancerous conditions can push the same markers up and the test cannot show where the marker came from.
- Some people with cancer never produce a high level of the marker linked to their disease, which gives a false negative.
- Many cancers have no reliable marker at all.
Main Types of Cancer Blood Tests
These tests fall into four groups.
- Tumour marker tests: These measure proteins released by cancer cells or by normal cells reacting to cancer. CA-125, CA 19-9, PSA, AFP and CEA belong here.
- Blood cell tests: A complete blood count and a peripheral smear examine red cells, white cells, and platelets. They are the first step when a blood cancer such as leukaemia is suspected.
- Organ function tests: Liver, kidney, and calcium levels show how cancer or its treatment is affecting the body. They do not point to a cancer type.
- Specialist biomarker tests: Oncologists order these to look for tumour DNA or treatment-linked markers, which helps in choosing therapy.
A routine blood count often gives the first hint of blood cancer before any marker is ordered.
Tumour Markers at a Glance
The chart below lines up the five markers against the cancers they are linked with and the ordinary conditions that can also raise them.
The chart below lines up the five markers against the cancers they are linked with and the ordinary conditions that can also raise them.
Common Cancer Markers and Their Uses
- CA-125 (Ovarian Cancer):
- Used to monitor treatment response and detect recurrence.
- Non-cancer causes of raised levels include ovarian cysts, endometriosis, cervicitis and benign liver disease.
- CA 19-9 (Pancreatic Cancer):
- Also associated with bile duct, gallbladder and stomach cancers.
- Used to track treatment response and recurrence.
- Non-cancer causes of raised levels include pancreatitis, cholangitis and obstructive jaundice.
- PSA (Prostate Cancer):
- Supports diagnosis, treatment monitoring and recurrence checks.
- Non-cancer causes of raised levels include an enlarged prostate and prostatitis.
- AFP (Liver and Germ Cell Tumours):
- Supports diagnosis and treatment monitoring.
- Non-cancer causes of raised levels include viral hepatitis, chronic liver disease and pregnancy.
- CEA (Colorectal Cancer):
- Mainly used to monitor treatment response and detect recurrence.
- Non-cancer causes of raised levels include smoking, peptic ulcers, inflammatory bowel disease and pancreatitis.
The Five Tumour Marker Tests at Unipath
None of these five tests needs fasting and all are processed in NABL-accredited laboratories.
- CA-125: Linked mainly to epithelial ovarian cancer, where it tracks treatment response and flags recurrence. Only about half of stage I cases show a raised level, and no major society recommends it as a routine screening test. The report is ready the same day. Details are on the Unipath CA-125 test page.
- CA 19-9: The marker used most often in pancreatic cancer and also raised in some bile duct, gallbladder, and stomach cancers. Roughly 5 to 10% of people are Lewis antigen negative and do not make CA 19-9 at all, so a normal value can mislead. The report is ready the same day. Details are on the Unipath CA 19-9 test page.
- PSA (for men only): Prostate-specific antigen supports the diagnosis of prostate cancer, tracks treatment, and checks for recurrence. An enlarged prostate or prostatitis can also lift it, so a high value leads to further tests rather than a diagnosis. Unipath lists age-based reference limits that rise from 2.5 ng/mL below age 50 to 6.5 ng/mL at 70 and above. Details are on the Unipath PSA test page.
- AFP: Used mainly for liver cancer and for germ cell tumours of the testis and ovary. A normal level sits below 20 ng/mL. Viral hepatitis, chronic liver disease, and pregnancy can raise it, while up to 20% of liver cancers never do. The report is ready the same day. Details are on the Unipath AFP test page.
- CEA: Used for colorectal cancer, mainly to follow treatment and catch recurrence, with repeat testing every one to three months during treatment of advanced disease. Smoking lifts the level, and the usual upper limit is about 2.5 ng/mL in non-smokers against 5 ng/mL in smokers. The report is ready the same day. Details are on the Unipath CEA test page.
What Blood Tests Still Cannot Find
The cancers at the top of India’s list show the gap. Breast and oral cavity cancer together account for more than 4,43,000 of the estimated new cases, yet neither has a blood marker suitable for screening. CA 15-3 and CA 27-29 follow advanced breast cancer during treatment but do not find it. Oral cancers are caught by examination and biopsy. Lung cancer, third on the list, has no screening blood test either. A normal tumour marker report says nothing about any of these and anyone with cancer symptoms in those organs needs a clinical examination despite the report outcomes.
Cancer Screening Tests and Where Blood Tests Fit
Cancer screening tests look for disease in people who have no symptoms. Which ones apply depends on age, sex, and personal risk. Tumour markers are rarely among them. A published review calls CA 19-9 an ineffective screening marker, notes that no major society recommends routine CA-125 screening and reports that guidelines disagree on AFP. Blood markers earn their place in diagnosis support, monitoring, and follow-up instead.
How to Read a Tumour Marker Result
One number says little. Direction says more. A level that climbs across three tests means more than a single mildly raised value and a level that falls after treatment is a good sign. Different laboratories use different assay methods, so serial results are best compared from the same laboratory.
Before the Test
The sample is a routine blood draw and none of the five tests requires fasting. The phlebotomist should know about recent infections, any procedure on the prostate or liver, and current medicines or supplements, since these can shift a marker. Each report also prints its own reference range and that printed range, not a figure picked up online, is the one to compare against. A detailed TRF (Test Requisition Form) is mandatory to be filled at the time of sample collection.
Cancer Risk Factors That Shape Testing
Cancer risk factors raise the odds of disease without deciding the outcome. Age leads the list, since most people are diagnosed at 65 or older. Smoking, heavy alcohol use, excessive sun exposure, and obesity follow. A small share of cancers traces back to inherited mutations. Chronic conditions such as ulcerative colitis raise the risk of certain cancers, and workplace chemicals such as asbestos and benzene add to it. Yet most cancers occur in people with no known risk factor, which is why a clean risk profile or a normal marker never amounts to a guarantee.
Cancer Early Warning Signs Worth a Doctor’s Visit
Cancer early warning signs are easy to dismiss because most have ordinary causes. Cancer awareness starts with knowing which ones persist. Common cancer symptoms include the following.
- Persistent fatigue
- A lump or thickened area under the skin
- Unintended weight loss or gain
- A sore that does not heal or a mole that changes
- Yellowing or darkening of the skin
- Changes in bowel or bladder habits
- A cough that will not clear, hoarseness, or trouble swallowing
- Ongoing indigestion or discomfort after eating
- Unexplained fevers, night sweats, bleeding, or bruising
None of these is specific to cancer. A sign that persists is the cue to see a doctor, who decides which investigations fit. A marker test may be one of them, but it never replaces a thorough examination by a specialist doctor.
Who Should Consider Tumour Marker Testing?
The decision belongs with a doctor. Three situations account for most requests.
- Cancer already diagnosed or treated: Markers give a baseline, track the response, and watch for recurrence.
- Higher risk: Strong cancer risk factors such as a family history, an inherited risk, or chronic liver disease may lead the doctor to pick the marker that matches the concern. A family history does not call for every marker, only the one tied to the cancer that runs in the family.
- Cancer symptoms pointing to one organ: Persistent changes tied to a single organ can justify the matching marker, read together with other findings.
A full panel of every marker for a healthy adult usually produces false alarms rather than early diagnoses. The arithmetic explains it. In a study of 70,940 adults without symptoms, CA 19-9 had a positive predictive value of 0.9%, meaning fewer than 1 in 100 positive results pointed to the disease it was meant to find. A review of CEA put its sensitivity for colorectal cancer screening at just 12%.
Newer Tests: Multi-Cancer Detection
Blood tests that screen for signals of several cancers from one sample are sold in some countries. According to the National Cancer Institute, the US Food and Drug Administration has not authorized any of them, and no trial has shown that they lower cancer deaths. In at least one study, about half of the people with a positive result had no cancer found after a year of follow-up. A negative result does not rule cancer out either.
Where to Test and How to Book
Unipath serves Ahmedabad, Surat, Vadodara and Jamnagar, Kolkata, Siliguri, Jaipur, Mumbai, Indore, Srinagar, Hyderabad and many other cities and towns in India. Cancer awareness also means knowing what a test cannot do, so the five markers above are best used with a doctor’s guidance. Anyone who wants a wider health screen can ask about Unifit health packages at the same time.
Unipath Diagnostic Services: Serviceable Cities
Ahmedabad • Surat • Vadodara • Kolkata • Jaipur • Mumbai • Siliguri • Jamnagar • Indore • Srinagar
For test bookings and inquiries: Contact Unipath
Disclaimer
Unipath does not represent or warrant that the content or information provided through our blog is accurate, complete, or current, nor that our blog content will be uninterrupted or error-free. We do not guarantee that any defects in our blog content will be corrected or that our server or the server hosting them is free of viruses or other harmful components. Unipath makes no warranties or representations regarding the use of materials in our blog content concerning their correctness, accuracy, adequacy, usefulness, timeliness, reliability, or otherwise, to the fullest extent permitted by applicable law. Information available via our platform and blog content may reference products, programmes, or services not available in your region. You understand and acknowledge that your sole and exclusive remedy for any defect in or dissatisfaction with our blog content is to cease using it.
References and Citations
[1] National Cancer Institute, Tumor Marker Tests in Common Use
[2] MedlinePlus, Tumor Marker Tests
[3] International Agency for Research on Cancer, GLOBOCAN India Fact Sheet
[4] World Journal of Oncology, A Primer on Commonly Used Cancer Markers
[5] National Cancer Institute, Questions and Answers about Multi-Cancer Detection Tests
[6] Mayo Clinic, Cancer Symptoms and Causes

